8-K: Prelude Therapeutics Announces Promising Preclinical Data on SMARCA2 and KAT6A Degraders at AACR Annual Meeting

Prelude Therapeutics presents new preclinical data at the AACR Annual Meeting for its selective SMARCA2 degrader PRT3789 and KAT6A degraders, showcasing potential for improved cancer treatment.

Summary

• Prelude Therapeutics announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting.
• The data highlights the mechanism of action of PRT3789, a highly selective SMARCA2 degrader currently in early clinical development.
• Preclinical data from Prelude's selective KAT6A degrader discovery program demonstrates potential for a differentiated efficacy and safety profile.
• PRT3789 is currently under evaluation in Phase 1 and Phase 2 studies in patients with advanced solid tumors with loss of SMARCA4 (NCT05639751 and NCT06682806).
• Prelude believes it has identified a series of first-in-class, sub-nanomolar, selective and readily orally bioavailable KAT6A degraders now advancing to candidate nomination.
• Pre-clinical data presented demonstrate that Preludes selective KAT6A degraders drive significantly deeper anti-cancer responses compared to non-selective KAT6A/B inhibitors across multiple KAT6A-amplified tumors.
• The KAT6A degraders also show sustained activity in ESR1and Pi3Kalpha-mutated cells, as well as endocrine therapyand CDK4/6i-resistant cells.
• The KAT6A degraders deliver robust in vivo target engagement and deep tumor regressions, including complete regressions, in breast and lung cancer xenografts as a monotherapy at low oral daily doses.
• The KAT6A degraders display reduced hematologic toxicity compared to KAT6A/B inhibitors.

Sentiment

Score: 8

Explanation: The announcement is positive due to promising preclinical data and potential for improved cancer therapies. The focus on selectivity and reduced toxicity contributes to the positive sentiment.

Positives

• PRT3789 is advancing in early clinical development for patients with SMARCA4 mutated cancers.
• Prelude's KAT6A degraders show potential for improved hematological safety compared to KAT6A/B inhibitors.
• The KAT6A degraders demonstrate robust anti-cancer activity in preclinical models.
• The KAT6A degraders show sustained activity in ESR1and Pi3Kalpha-mutated cells, as well as endocrine therapyand CDK4/6i-resistant cells.
• The KAT6A degraders deliver deep tumor regressions, including complete regressions, in breast and lung cancer xenografts as a monotherapy at low oral daily doses.

Risks

• The timing and results of biotechnology development and potential regulatory approval is inherently uncertain.
• Forward-looking statements are subject to risks and uncertainties that may cause Prelude's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Prelude's ability to advance its product candidates.

Future Outlook

The company anticipates continued discovery, preclinical and clinical development activities for its product candidates, and believes in the potential safety, efficacy, benefits and addressable market for these candidates.

Management Comments

• Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude, stated, 'We are pleased to provide further preclinical data on the discovery of our lead selective SMARCA2 degrader PRT3789, currently advancing in early clinical development for patients with SMARCA4 mutated cancers.'
• Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude, stated, 'We are also delighted to report initial preclinical data from our selective KAT6A degrader discovery program.'
• Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude, stated, 'These data demonstrate that selectively degrading KAT6A results in robust anti-cancer activity in various pre-clinical models of breast cancer and other solid tumors.'
• Peggy Scherle, Ph.D., Chief Scientific Officer of Prelude, stated, 'We believe that our first-in-class, highly potent KAT6A selective degraders have the potential to expand the therapeutic reach of KAT6A/B inhibitors currently advancing in the clinic, while addressing safety challenges associated with non-selective approaches to this clinically validated target.'

Industry Context

The announcement highlights Prelude's focus on precision oncology and targeted protein degradation, aligning with the industry's growing interest in developing more selective and effective cancer therapies. The development of SMARCA2 and KAT6A degraders addresses unmet needs in specific cancer subtypes and aims to overcome limitations of existing treatments.

Comparison to Industry Standards

• The document references a dual KAT6A/B inhibitor that has shown promising efficacy in ER+/HER2breast cancer, but with potential safety concerns like neutropenia, suggesting that Prelude's selective KAT6A degraders aim to improve upon this by offering better hematological safety.
• The document cites research on histone lysine acetyltranferase inhibitors as an emerging class of drugs for cancer therapy, placing Prelude's KAT6A degrader program within this broader context of epigenetic cancer treatments.

Stakeholder Impact

• Positive impact on shareholders due to promising preclinical data.
• Potential benefit to cancer patients through development of new and more effective therapies.
• Opportunity for employees to contribute to innovative cancer research.
• Potential partnerships with other companies in the pharmaceutical industry.

Next Steps

• Continue evaluation of PRT3789 in Phase 1 and Phase 2 studies.
• Advance selective KAT6A degraders to candidate nomination.
• Continue research into other precision oncology targets.
• Leverage expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners.

Key Dates

Keywords

KAT6A degraders, SMARCA2 degrader, PRT3789, Prelude Therapeutics, AACR, Oncology, Cancer, Degraders